Abstract
Objective
The MEDCOR trial is a double-blind, randomized study aiming at demonstrating the superiority
of molsidomine (direct NO donor) over placebo, used as add-on treatments, on improving
endothelial function (EF) after 12 months, in stable angina patients undergoing percutaneous
coronary intervention.
Methods
EF was assessed by peripheral vasodilator response (i.e. Endoscore) using arterial
tonometry and by several biomarkers, in terms of changes versus baseline after a one-year
treatment.
Results
The change in Endoscore was +75 ± 130% in placebo group and +39 ± 145% in molsidomine
group (p = 0.143). There was a decrease in sICAM-1 with molsidomine (−6%) and an increase
with placebo (+6%). The MPO activity/antigen ratio slightly increased with placebo
(+9%) and strongly decreased with molsidomine (−42%) (p = 0.020).
Conclusion
The MEDCOR trial was not able to demonstrate significant differences between molsidomine
and placebo for all parameters, except the MPO activity/antigen ratio which significantly
decreased with molsidomine (p = 0.020 versus placebo).
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Approaches for non-invasive assessment of endothelial function: focus on peripheral arterial tonometry.Neth. Heart J. 2013; 21: 214-218
- Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris.Int. J. Cardiol. 2005; 98: 79-89
- Tolerability to 1-year treatment with once-daily molsidomine in patients with stable angina.Adv. Ther. 2006; 23: 601-614
- Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability during cholesterol lowering in rabbits.J. Cardiovasc. Pharmacol. 2003; 41: 970-978
- Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease.J. Cardiovasc. Pharmacol. 2000; 35: 560-563
- Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina.Atherosclerosis. 2005; 180: 399-405
- Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial.J. Cardiovasc. Transl. Res. 2014; 7: 226-231
- Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events.Eur. Heart J. 2010; 31: 1142-1148
- Circulating biomarkers.Thromb. Res. 2012; 130: S12-S15
- An update on the role of markers of inflammation in atherosclerosis.J. Atheroscler. Thromb. 2010; 17: 1-11
- Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?.Clin. Chem. 2009; 55: 1462-1470
- Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease.Curr. Top. Med. Chem. 2013; 13: 115-138
- Markers of endothelial dysfunction after cardiac surgery: soluble forms of vascular-1 and intercellular-1 adhesion molecules.Med. (Kaunas). 2009; 45: 434-439
- Microparticles, vascular function, and atherothrombosis.Circ. Res. 2011; 109: 593-606
- Leukocyte-derived microparticles in vascular homeostasis.Circ. Res. 2012; 110: 356-369
- Microparticles as biomarkers of vascular dysfunction in metabolic syndrome and its individual components.Curr. Vasc. Pharmacol. 2014; 12: 483-492
- Endothelial microparticles as conveyors of information in atherosclerotic disease.Atherosclerosis. 2014; 234: 295-302
- Myeloperoxidase and cardiovascular disease.Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1102-1111
- The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study.BMC Med. Res. Methodol. 2001; 1): 6
- Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans.J. Am. Coll. Cardiol. 2001; 38: 1096-1101
- Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism.J. Am. Coll. Cardiol. 2007; 49: 1289-1295
Article info
Publication history
Published online: April 07, 2015
Accepted:
March 30,
2015
Received in revised form:
March 9,
2015
Received:
December 16,
2014
Identification
Copyright
© 2015 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
